Illimis secures $42 million in Series B funding to advance GAIA-based Alzheimer’s therapies.
Amount Raised
$42 Million
Round Type
Series B
SeoulBiotechnologyHealth CareTherapeuticsInvestors
Description
Illimis has successfully raised $42 million in a Series B funding round to advance its efforts in developing therapeutics for Alzheimer’s disease. The funding will support Illimis in furthering research and development of its GAIA-based therapies. This investment marks a significant step for the company as it works toward creating innovative solutions for Alzheimer's disease.
Quick answer
Illimis Therapeutics raised $42 Million in a Series B round, dated July 14, 2025. Investors: Dayli Partners, GS Ventures, Quad Asset Management, Korea Development Bank and Woori Venture Partners. Illimis Therapeutics is based in Seoul, Seoul, South Korea.
- How much did Illimis Therapeutics raise?
- Illimis Therapeutics raised $42 Million in a Series B round on July 14, 2025.
- Who invested in Illimis Therapeutics?
- Dayli Partners, GS Ventures, Quad Asset Management, Korea Development Bank and Woori Venture Partners are named as investors in this round.
- What does Illimis Therapeutics do?
- Illimis Therapeutics is a biotechnology company focused on developing therapeutics for CNS and immune diseases using its innovative GAIA platform.
- Where is Illimis Therapeutics based and how big is it?
- Illimis Therapeutics is based in Seoul, Seoul, South Korea. Fundz records about 20 employees.
- Who are the decision-makers at Illimis Therapeutics?
- Fundz holds 1 contact at Illimis Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Illimis Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Immuneering raised $25M on August 26, 2025.
- QurAlis raised $20M on August 21, 2025.
- Calidi Biotherapeutics raised $6.9M (Post-IPO Equity) on August 21, 2025.
- CILA Therapeutics raised an undisclosed amount (Grant) on August 15, 2025.
- Eyestem raised $10M (Series B) on August 11, 2025.
- Tevogen Inc. raised $1M (Funding Round) on August 7, 2025.
Who to call at Illimis Therapeutics, and when
A new round usually means Illimis Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Illimis Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Illimis Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Illimis Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Illimis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansIllimis Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.